Dark Horse Consulting Group Expands into China, Appoints Kang Liu as Senior Director, Head of China

WALNUT CREEK, Calif. and SHANGHAI, Aug. 11, 2026 (GLOBE NEWSWIRE) — Dark Horse Consulting Group (DHCG), a leading life sciences consulting firm specializing in advanced therapies, today announced the formation of Dark Horse Consulting China and the appointment of Kang Liu, Ph.D. as its inaugural hire. The new office, located in Shanghai, reflects DHCG’s strategic commitment to helping biotherapeutic developers capitalize on China’s rapidly advancing life sciences ecosystem, including its world-class CDMO and CRO infrastructure, streamlined regulatory pathways to first-in-human (FIH), and growing role as a global hub for clinical data generation.

The timing of this expansion is deliberate. China’s life sciences ecosystem has reached an inflection point: its CDMO and CRO infrastructure now rivals the best in the world, its regulatory frameworks are maturing rapidly, and its Investigator Initiated Trial (IIT) pathway offers developers a credible, cost-effective route to generating FIH data. To head DHCG’s China practice, the firm has appointed Kang Liu, a seasoned life sciences leader with over 13 years of on-ground experience across CRO/CDMO operations and Cell & Gene Therapy with deep relationships across China’s nonclinical, clinical, manufacturing, and regulatory landscape.